CAS 112809-51-5

Letrozole

Description:

Letrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Its mechanism of action involves the inhibition of aromatase, an enzyme responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This reduction is crucial as many breast cancers are fueled by estrogen. Letrozole is typically administered orally and is known for its relatively favorable side effect profile compared to other hormonal therapies. Common side effects may include hot flashes, joint pain, fatigue, and potential bone density loss. The chemical structure of letrozole includes a triazole ring, contributing to its pharmacological properties. It is classified under the category of antineoplastic agents and is often part of adjuvant therapy following surgery or as a first-line treatment for advanced breast cancer. Letrozole's efficacy and safety have made it a standard option in breast cancer management, and ongoing research continues to explore its potential in other malignancies and therapeutic contexts.

Formula: C₁₇H₁₁N₅

InChI: InChI=1/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

InChI key: InChIKey=HPJKCIUCZWXJDR-UHFFFAOYSA-N

SMILES: C(C1=CC=C(C#N)C=C1)(C2=CC=C(C#N)C=C2)N3C=NC=N3

Synonyms:

• 4,4'-(1h-1,2,4-Triazol-1-Ylmethylene) Bis-Benzonitrile
• 4,4'-(1h-1,2,4-Triazol-1-Ylmethylene)Bisbenzonitrile
• 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
• 4-[1-(4-Cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile
• Benzonitrile, 4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis-
• Cgs 20267
• Femara
• Lelrozol
• Lerozole
• Letocor
• Letoripe
• Letrazole
• Letrof L Lil
• Letroz
• Letrozol
• Letrozole
• 4,4'-(1H-1,2,4-Triazole-1-ylmethylene)bisbenzonitrile
• Letrozole99%
• CGS-20267, Femara
• letrozolex
• 4,4'-[(1H-1,2,4-Triazole-1-yl)methylene]dibenzonitrile
• 1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE

Letrozole

CAS: 112809-51-5

Formula: C₁₇H₁₁N₅

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 285.31

Ref: 3B-L0248

Letrozole

CAS: 112809-51-5

Letrozole

Formula: C₁₇H₁₁N₅

Purity: 100.0%

Color and Shape: Yellow

Molecular weight: 285.10145

Ref: 47-1234

LETROZOLE CRS

CAS: 112809-51-5

LETROZOLE CRS

Ref: 41-Y0000685

Letrozole

CAS: 112809-51-5

Aromatic or modified aromatic drugs with nitrogen hetero-atom(s) only, not elsewhere specified or included

Formula: C₁₇H₁₁N₅

Color and Shape: White Yellow Crystalline Powder

Molecular weight: 285.31 g/mol

Ref: 45-1356971

Letrozole

CAS: 112809-51-5

Letrozole (CGS 20267) is an Aromatase Inhibitor. The mechanism of action of letrozole is as an Aromatase Inhibitor.

Formula: C₁₇H₁₁N₅

Purity: 98.67% - 99.84%

Color and Shape: White To Off-Whitecrystalline Powder

Molecular weight: 285.3

Ref: TM-T1590

Letrozole

CAS: 112809-51-5

Letrozole

Purity: ≥95%

Molecular weight: 285.308g/mol

Ref: 54-OR98219

Letrozole

CAS: 112809-51-5

Formula: C₁₇H₁₁N₅

Color and Shape: White To Off-White Solid

Molecular weight: 285.31

Ref: 4Z-L-163

Letrozole

CAS: 112809-51-5

Formula: C₁₇H₁₁N₅

Color and Shape: Neat

Molecular weight: 285.30

Ref: 04-C14628500

Letrozole

CAS: 112809-51-5

Color and Shape: Neat

Ref: 86-MM1143.00

Letrozole

CAS: 112809-51-5

Formula: C₁₇H₁₁N₅

Purity: ≥ 98.0% (anhydrous basis)

Color and Shape: White to off-white powder

Molecular weight: 285.30

Ref: 7W-GP1426

1-[Bis(4-cyanophenyl)methyl]-1,2,4-triazole

CAS: 112809-51-5

Purity: 97.0%

Color and Shape: Solid

Molecular weight: 285.30999755859375

Ref: 10-F036495

Letrozole

CAS: 112809-51-5

Applications A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic.
References Bhatnagar, A.S., et al: J. Steroid Biochem. Mol. Biol., 37, 1021 (1990), Pfister, C.U., et al.: J. Pharm. Sci., 83, 520 (1994), Lipton, A., et al.: Cancer, 75, 2132 (1995),

Formula: C₁₇H₁₁N₅

Color and Shape: Yellow

Molecular weight: 285.30

Ref: TR-L330100

Letrozole

Controlled Product

CAS: 112809-51-5

Non-steroidal inhibitor of aromatase

Formula: C₁₇H₁₁N₅

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 285.3 g/mol

Ref: 3D-FL24873

Letrozole - Bio-X ™

Controlled Product

CAS: 112809-51-5

Letrozole is an aromatase inhibitor drug that is used in the treatment of breast cancer in postmenopausal women. It is a non-steroidal type II inhibitor that blocks the active site and thus blocking the electron transfer chain of CYP19A1. As a result of this, the conversion of androgen to estrogen is inhibited.

Formula: C₁₇H₁₁N₅

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 285.3 g/mol

Ref: 3D-BL164620

Letrozole

Controlled Product

CAS: 112809-51-5

Letrozole is a non-steroidal aromatase inhibitor, which is synthesized chemically. This product acts by inhibiting the aromatase enzyme, thus reducing estrogen production in the body. Estrogen plays a critical role in the proliferation of hormone-sensitive breast cancer cells, and by lowering its levels, Letrozole effectively impedes cancer growth.

Formula: C₁₇H₁₁N₅

Molecular weight: 285.30 g/mol

Ref: 3D-Q-201291

4,4'-((1H-1,2,4-Triazol-1-yl)methylene)dibenzonitrile

CAS: 112809-51-5

Formula: C₁₇H₁₁N₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 285.3027

Ref: IN-DA0078V9